PROGNOSTIC IMPLICATION OF IPSS AND IPSS-R FOR PATIENTS WITH LOWER-RISK MDS TREATED WITH HYPOMETHYLATING AGENTS

被引：0
|
作者：
Moon, J. H. [1 ]
Sohn, S. K. [1 ]
Sook, A. Jae [2 ]
Kim, H. J. [2 ]
Song, M. K. [3 ]
Chung, J. S. [3 ]
Lim, S. N. [4 ]
Bae, S. H. [5 ]
机构：
[1] Kyungpook Natl Univ Hosp, Deagu, South Korea
[2] Cheonnam Natl Univ, Hwasun Hosp, Cheonnam, South Korea
[3] Busan Natl Univ Hosp, Pusan, South Korea
[4] Inje Univ, Paik Hosp, Pusan, South Korea
[5] Daegu Catholic Univ, Med Ctr, Deagu, South Korea
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P919
引用
收藏
页码：345 / 346
页数：2
相关论文
共 50 条
  • [1] Role Of Hypomethylating Agents For Patients With Lower-Risk Myelodysplastic Syndrome Defined By IPSS and IPSS-R
    Moon, Joon Ho
    Sohn, Sang Kyun
    Ahn, Jae Sook
    Kim, Yeo-Kyeoung
    Kim, Hyeoung Joon
    Song, Moo-Kon
    Shin, Ho-Jin
    Chung, Joo-Seop
    Song, Ik Chan
    Jo, Deog-Yeon
    Lim, Sung Nam
    Lee, Ho Sup
    Kim, Yang Soo
    Bae, Sung Hwa
    BLOOD, 2013, 122 (21)
  • [2] Prognostic implication of Revised International Prognostic Scoring System (IPSS-R) for the patients treated with hypomethylating agents
    Moon, J.
    Sohn, S. K.
    Lim, S. N.
    Bae, S. H.
    Kim, H. J.
    Kim, Y. K.
    LEUKEMIA RESEARCH, 2013, 37 : S81 - S82
  • [3] Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine
    Massimo Breccia
    Adriano Salaroli
    Giuseppina Loglisci
    Giuliana Alimena
    Annals of Hematology, 2013, 92 : 411 - 412
  • [4] Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine
    Breccia, Massimo
    Salaroli, Adriano
    Loglisci, Giuseppina
    Alimena, Giuliana
    ANNALS OF HEMATOLOGY, 2013, 92 (03) : 411 - 412
  • [5] Comparison of International Prognostic Scoring System (IPSS) and Revised IPSS (IPSS-R) in myelodysplastic syndromes (MDS).
    Mushtaq, Muhammad Umair
    Ali, Abdullah
    Morita, Kiyomi
    Pinheiro, Ronald
    Baig, Muhammad
    Raza, Azra
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [6] Improved Prognostic Assessment Of Patients With MDS By IPSS-R and MDS-CI
    van Spronsen, Margot
    van Spronsen, Margot
    van de Loosdrecht, Arjan
    Chamuleau, Martine E. D.
    BLOOD, 2013, 122 (21)
  • [7] Stratification with monosomal karyotype improves prognostic value of IPSS-R in MDS patients treated with AZA
    Cluzeau, T.
    Mounier, N.
    Karsenti, J. M.
    Gastaud, L.
    Garnier, G.
    Re, D.
    Gutnecht, J.
    Montagne, N.
    Raynaud, S.
    Cassuto, J. P.
    LEUKEMIA RESEARCH, 2013, 37 : S80 - S80
  • [8] RISK SCORING SYSTEM USING IPSS-R, LDH AND PERFORMANCE STATUS TO PREDICT THE OUTCOMES OF PATIENTS WITH LOWER RISK MYELODYSPLASTIC SYNDROME TREATED WITH HYPOMETHYLATING AGENTS
    Sohn, S.
    Moon, J.
    Lee, Y.
    Lim, S.
    Bae, S.
    Hyun, M.
    HAEMATOLOGICA, 2013, 98 : 311 - 311
  • [9] Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
    Sekeres, M. A.
    Swern, A. S.
    Fenaux, P.
    Greenberg, P. L.
    Sanz, G. F.
    Bennett, J. M.
    Dreyfus, F.
    List, A. F.
    Li, J. S.
    Sugrue, M. M.
    BLOOD CANCER JOURNAL, 2014, 4 : e242 - e242
  • [10] Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
    M A Sekeres
    A S Swern
    P Fenaux
    P L Greenberg
    G F Sanz
    J M Bennett
    F Dreyfus
    A F List
    J S Li
    M M Sugrue
    Blood Cancer Journal, 2014, 4 : e242 - e242
12345